Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma : a study of epidemiologic risk factors, histologic features, and prognosis.
This study explores the interaction of HER with three aspects of axillary lymph node negative breast carcinoma : epidemiologic risk factors, tumor histopathology, and prognosis.
Immunohistochemical staining for HER was performed on 10% formalin fixed paraffin embedded primary carcinomas from 440 patients with negative axillary lymph nodes with a median follow-up of 119 months.
The immunohistochemical expression, or lack thereof, of HER did not prove to be prognostically significant in this group of patients with axillary lymph node negative breast carcinoma.
There was also no consistent association with epidemiologic risk factors.
The results obtained in this study suggest that the immunohistochemical demonstration of HER is not a reliable prognostic indicator for patients with axillary lymph node negative breast carcinoma.
This marker was not associated with major epidemiologic risk factors ; however, there was a significant correlation between HER and the phenotypic features of breast carcinoma because medullary carcinoma is rarely HER (+). Although the associations may not be a strong enough basis for refining the classification of breast carcinoma, they could be useful for diagnosing individual patients.
The changes in HER that are detectable by the immunohistochemical methods used in this study probably do not occur in the earliest stages of mammary carcinogenesis.
Cancer 1995 ; 75 : 1320-6.
Mots-clés Pascal : Epithélioma, Glande mammaire, Homme, Immunohistochimie, Exploration, Gène onc cellulaire, Protooncogène, Expression génique, Facteur risque, Epidémiologie, Pronostic, Glande mammaire pathologie, Tumeur maligne, Gène HER2, Gène erbB2
Mots-clés Pascal anglais : Carcinoma, Mammary gland, Human, Immunohistochemistry, Exploration, C-Onc gene, Protooncogene, Gene expression, Risk factor, Epidemiology, Prognosis, Mammary gland diseases, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0386609
Code Inist : 002B20E02. Création : 01/03/1996.